Every 10-Q that Opus Genetics, Inc. (IRD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRD filings page.
Opus Genetics, Inc. reported a net loss of $73,633 thousand for the six months ended June 30, 2026, compared with $15,614 thousand a year earlier, as license and collaboration revenue declined to $2,912 thousand from $7,252 thousand and operating expenses increased, led by research and development of $21,784 thousand and general and administrative of $11,972 thousand. Results were further affected by a $44,190 thousand loss from fair value changes in warrants and new notes, partially offset by other income of $2,514 thousand.
Cash and cash equivalents rose to $88,812 thousand at June 30, 2026, with total assets of $92,968 thousand, but stockholders’ equity shifted to a deficit of $12,986 thousand, driven by warrant liabilities of $62,145 thousand, fair-value debt of $34,932 thousand and an accumulated deficit of $262,222 thousand. The company strengthened liquidity through a $25.0 million Series B preferred financing (now converted to common stock), a $35.0 million initial tranche under a secured note purchase agreement that permits up to $155.0 million of funding, a $5.0 million common stock purchase tied to that facility, at-the-market share sales and warrant and option exercises. Management states that existing cash resources are expected to fund operations for at least 12 months while it advances AAV-based gene therapy programs and ophthalmic collaborations, including ongoing revenue from the Viatris license.
Opus Genetics, Inc. reported sharply higher first‑quarter 2026 losses driven mainly by non‑cash warrant revaluation, while strengthening its cash position and advancing its gene therapy pipeline.
License and collaboration revenue from the Viatris agreement was $2.2 million, down from $4.4 million a year earlier as reimbursed R&D activity declined. Total operating expenses rose to $16.5 million, reflecting higher research and development spending of $10.6 million as clinical programs progressed.
The company recorded a net loss of $65.5 million versus $8.2 million in the prior‑year quarter, largely due to a $51.4 million fair value loss on warrant liabilities. Cash and cash equivalents increased to $60.0 million at March 31, 2026, helped by a $25.0 million Series B preferred stock financing and $2.3 million raised via the at‑the‑market program. Management states that, including approximately $34.5 million of April 2026 proceeds from a new Oberland Capital senior secured notes facility, available liquidity is expected to fund operations for at least 12 months. Opus continues to advance lead AAV gene therapy OPGx‑LCA5 toward a Phase 3 trial and is recruiting for OPGx‑BEST1, while maintaining multiple academic and foundation funding partnerships.
Opus Genetics (IRD) filed its Q3 2025 10‑Q, reporting license and collaboration revenue of $3.079 million and a net loss of $17.454 million (basic and diluted loss per share $0.25). For the first nine months of 2025, revenue was $10.331 million with a net loss of $33.068 million.
Cash and cash equivalents were $30.815 million with total assets of $36.122 million. Warrant liabilities stood at $21.325 million, reflecting the March 2025 financings. Stockholders’ equity was $5.967 million. The company stated its cash is expected to fund operations for at least the next 12 months from the financial statement issuance date.
During 2025, Opus raised capital via an underwritten offering and private placement in March, an ATM program, and a related‑party funding agreement for the MERTK program. The Series A preferred stock converted into 14,145,374 common shares on May 5, 2025. Common shares outstanding were 64,544,096 at September 30, 2025, and 68,964,208 as of November 10, 2025.